Rituximab Biosimilar Immunological Preparation
A mixed immunological preparation containing rituximab monoclonal antibodies, used to treat non-Hodgkin lymphoma and rheumatoid arthritis. It is not put up in measured doses or for retail sale, so it falls under tariff item 3002.14.00.
Import Duty Rates by Country of Origin
| Origin Country | MFN Tariff | Surtaxes | Total Effective Rate |
|---|---|---|---|
| π¨π³China | Free | β | Free |
| π²π½Mexico | Free | β | Free |
| πΊπΈUnited States | Free | β | Free |
| π©πͺGermany | Free | β | Free |
| π―π΅Japan | Free | β | Free |
More Specific Codes
This product may fall under a more specific subheading:
Alternative Classifications
This product could be classified differently depending on its characteristics or intended use.
If put up in measured doses or in forms or packings for retail sale
The same product in retail packaging would be classified under the retail-sale subheading.
If formulated as a medicament with other active ingredients for therapeutic use
Medicaments containing mixed immunological products may fall under Chapter 30 heading 3004.
Not sure which classification is right?
The Tariff Assistant works through the GRI rules on your specific product to reach the right tariff item β and can price the duty on it in the same conversation.
Import Tips & Compliance
β’ Ensure the product is in bulk form, not packaged for retail sale, to qualify for this tariff item
β’ Have documentation showing the rituximab content and that it is mixed, as per Chapter 30 Note 2
β’ Verify if a Drug Identification Number (DIN) is required by Health Canada before import
Related Products under Tariff item 3002.14.00
Adalimumab Reference Product Bulk
A bulk mixed form of adalimumab (Humira) monoclonal antibody for rheumatoid arthritis treatment, supplied for further dilution. It is not in measured doses or retail packings, and qualifies as a mixed immunological product under chapter note 2.
Antibody Fragment Conjugate Mixture
A mixed biotechnological preparation containing antibody fragments and conjugates, designed for targeted drug delivery in immunology. It is supplied in bulk, not put up in measured doses or retail packings, and qualifies as a mixed immunological product under the chapter's definition.
Antibody Fragment Conjugate Mixture for Targeted Therapy
A blend of antibody fragments and conjugates for precise immune targeting in autoimmune diseases. It is a mixed, non-retail immunological product, including antibody conjugates as per Chapter 30 Note 2, so it falls under tariff item 3002.14.00.
Bevacizumab Biosimilar Mixture
A bulk mixed immunological product with bevacizumab monoclonal antibodies targeting VEGF for colorectal cancer therapy. It is not put up in measured doses or retail packings, and is classified as a mixed immunological product per chapter note 2.
Biotech Antibody and Chemokine Solution
A mixed solution of monoclonal antibodies (MAB) and chemokines for inflammation control, supplied in bulk for further processing. It is not in measured doses or retail packings, and is classified as a mixed immunological product per chapter note 2.
Blended Interferon-Alpha and Interleukin-2 Preparation
A mixed solution of recombinant interferon-alpha (IFN-Ξ±) and interleukin-2 (IL-2) for immunotherapy in viral infections and cancer. It is supplied in bulk, not in measured doses or retail packings, and qualifies as a mixed immunological product under chapter note 2.